GSK share price dips in London as Exdensur rollout and Feb 4 results loom
GSK shares slipped 0.65% to 1,840 pence in early London trading on Friday. The stock kicked off at 1,836 pence, fluctuating between 1,823 and 1,843 pence.
GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom
GSK shares edged up 0.34% to 1,823.75 pence early Thursday in London, recovering a bit after a 2.42% drop on Wednesday. Still, the stock is down 0.38% year to date.
FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives
Britain’s FTSE 100 turned lower on Wednesday, down 0.3% at 10,177.85, as dollar weakness pushed up sterling and pressured big overseas earners. GSK fell 2% and Experian slipped, while gold miner Endeavour Mining rose 3% and BP and Shell gained about 1%.
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus
GSK shares fell 1.8% to 1,828.5 pence by mid-morning Wednesday in London, retreating after two days higher. The stock slipped 34 pence from Tuesday’s close, with about 951,000 shares traded, per LSE data.
GSK share price rises after EU clears Arexvy for adults 18+ as earnings near
GSK shares climbed in early London action Tuesday following news the drugmaker secured European approval to expand its respiratory syncytial virus vaccine Arexvy for all adults 18 and older. By 0904 GMT, the stock had gained 0.7% to 1,841.5 pence.
GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+
GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.
GSK share price: China’s Trelegy asthma nod puts the stock in focus for Monday — what to watch next
Shares of GSK plc are set to draw attention when London trading resumes Monday, following news that China approved a new asthma indication for its Trelegy Ellipta inhaler. On Friday, the stock closed down 3.5 pence, or 0.19%, at 1,801 pence, with around 9 million shares changing hands.
GSK share price in focus after China clears Trelegy for asthma — what to watch next week
GSK plc shares slipped 0.2% to 1,801 pence on Friday following news that China approved Trelegy Ellipta for adults with uncontrolled asthma. With London trading closed for the weekend, investors will have to wait until Monday to assess the impact of the new label.
Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus
Pfizer shares climbed Thursday after the company announced two deals highlighting its strategy to transform its business. By afternoon, the stock had gained roughly 0.8%, reaching $26.10.
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk
GSK shares ticked up in early London trading Thursday as investors weighed the drugmaker’s push into a mid-stage food-allergy treatment alongside growing discussions over vaccine demand in the U.S.
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share
Rapt Therapeutics surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech.
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug
RAPT Therapeutics shares jumped about 64% Tuesday, reaching $57.54 in early Nasdaq action. The uptick followed Britain’s GSK unveiling a cash acquisition offer of $58 per share for the U.S. biotech firm.
GSK share price slips into the weekend as investors brace for Feb. 4 results
GSK shares dipped 1.7% on Friday, ending at 1,816.5 pence. That’s underperforming the flat FTSE 100, with trading volume ticking above recent levels.
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results
Shares of GSK plc slipped 1.7% to 1,817 pence on Friday, lagging behind a flat FTSE 100 as volume spiked late in the session. The stock closed 11.7% below its 52-week peak of 2,058 pence reached on Dec. 19. Trading volume hit 12.6 million shares, well above the 50-day average of 8.2 million.
GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus
GSK plc’s shares traded in the U.S. climbed 1.8% on Wednesday, closing at $50.79. The stock remains in the spotlight heading into Thursday’s session.
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next
GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination.
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors
Shares of GSK plc edged down 0.03% to 1,885.5 pence early Monday in London, after fluctuating between 1,870.5 and 1,885.5 pence during the session.
GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference
Shares of GSK plc face fresh legal uncertainty on Monday after AnaptysBio moved to dismiss part of a contract claim related to royalties for the cancer drug Jemperli. On Friday, GSK slipped 0.26% to 1,886 pence, just shy of its 52-week peak at 1,909.5. Technical traders are eyeing the 1,830 pence level, close to the 200-day moving average, as a key support zone.
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle
GSK said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than 1,800 patients across 29 countries. Chief Scientific Officer Tony Wood called the readout a “major advance”, and GSK said it defines a functional cure as losing a key viral protein and having no detectable virus DNA for at least 24 weeks after treatment ends. GSK
GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps
GSK plc shares rose nearly 1% in early London trade on Tuesday after the drugmaker said Japan had approved its bronchial asthma treatment Exdensur. Shares were up 0.96% at 1,838 pence by 0830 GMT. sharecast.com